Share-based Payment Arrangement, Expense of Aquestive Therapeutics, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aquestive Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Aquestive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,777,000, a 76% increase year-over-year.
  • Aquestive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,651,000, a 54% increase year-over-year.
  • Aquestive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7,099,000, a 164% increase from 2023.
  • Aquestive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,689,000, a 39% decline from 2022.
  • Aquestive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,381,000, a 36% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aquestive Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,651,000 $2,777,000 +$1,200,000 +76% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $7,451,000 $1,884,000 +$345,000 +22% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $7,106,000 $1,587,000 +$7,000 +0.44% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $7,099,000 $2,403,000 +$1,480,000 +160% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2025 2024 FY
Q3 2024 $5,619,000 $1,577,000 +$803,000 +104% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $4,816,000 $1,539,000 +$891,000 +138% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $3,925,000 $1,580,000 +$1,236,000 +359% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $2,689,000 $923,000 +$211,000 +30% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
Q3 2023 $2,478,000 $774,000 +$239,000 +45% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $2,239,000 $648,000 -$1,573,000 -71% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $3,812,000 $344,000 -$569,000 -62% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $4,381,000 $712,000 -$979,000 -58% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $5,360,000 $535,000 -$1,365,000 -72% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $6,725,000 $2,221,000 +$500,000 +29% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $6,225,000 $913,000 -$594,000 -39% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $6,819,000 $1,691,000 +$500,000 +42% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $6,319,000 $1,900,000 +$135,000 +7.6% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $6,184,000 $1,721,000 -$44,000 -2.5% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $6,228,000 $1,507,000 -$353,000 -19% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $6,581,000 $1,191,000 -$680,000 -36% 01 Oct 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $7,261,000 $1,765,000 -$105,000 -5.6% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $7,366,000 $1,765,000 -$45,000 -2.5% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $7,411,000 $1,860,000 +$340,000 +22% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $7,071,000 $1,871,000 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $1,870,000 +$634,000 +51% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $1,810,000 -$25,495,000 -93% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $1,520,000 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q3 2018 $1,236,000 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $27,305,000 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2

Aquestive Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,099,000 +$4,410,000 +164% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2025 2024 FY
2023 $2,689,000 -$1,692,000 -39% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
2022 $4,381,000 -$2,438,000 -36% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $6,819,000 +$238,000 +3.6% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $6,581,000 -$490,000 -6.9% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
2019 $7,071,000 -$22,869,000 -76% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $29,940,000 +$29,940,000 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
2017 $0 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.